The autologous CAR T-cell therapy axicabtagene ciloleucel (axi-cel) demonstrated effectiveness and safety consistent with the ZUMA-5 trial when used in real-world settings to treat a broader ...
Long-Term Efficacy and Safety of Lifileucel Tumor-Infiltrating Lymphocyte Cell Therapy in Patients With Advanced Melanoma: A 5-Year Analysis of the C-144-01 Study Axicabtagene ciloleucel (axi-cel) is ...
– ZUMA-5 Analysis Shows Median Progression-Free Survival of 62.2 Months and Median Duration of Response of 60.4 Months After Median Follow-Up of More Than Five Years – – Over Half of Patients Alive at ...
Patients with relapsed or refractory (r/r) follicular lymphoma live longer when they are treated with the novel anti-CD19 chimeric antigen receptor T-cell therapy axicabtagene ciloleucel (axi-cel; ...
The company states: “Kite, a Gilead (GILD) Company, announced results from a five-year follow-up analysis of ZUMA-5, a Phase 2 study of Yescarta in patients with relapsed/refractory non-Hodgkin ...
Dr Sattva S. Neelapu discusses data from the ZUMA-5 trial investigating the CAR T-cell therapy Yescarta in relapsed/refractory follicular lymphoma. Treatment with the CAR T-cell therapy Yescarta ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results